

Long-Acting Injectable Antiretroviral Therapy

Date: 6/23/2020

Time: 12:00 – 1:00 PM

Continuing Pharmacy Education Program
Clinical Pharmacy Associates, Inc. &
DC Department of Health
HIV/AIDS, Hepatitis, STD,
TD Administration

Who should attend: The program is designed for pharmacists in the DC HIV/AIDS Pharmacy Network and pharmacists in client organizations of CPA/MedNovations.

Needs Statement: Emerging antiretroviral drug development for treatment of persons living with HIV (PLWH) includes new injectable drugs and formulations. The injectable route of administration of antiretrovirals, first occurring with the FDA- approved drug ibalizumab, represents both opportunities and challenges for accessible, safe and efficacious use of treatment in clinical practice. Pharmacy professionals must be knowledgeable and provide essential pharmaceutical services to optimize injectable antiretrovirals in the community and organized health care settings.

Statement of Goal: To equip the practicing pharmacist professional with current knowledge regarding the drugs, role/s, use and operational considerations to employ injectable ARVs in the care of PLWH.

Activity Type: Knowledge

Objectives: After completing the program, participants should be able to:

- **Define** place in therapy for long-acting injectable antiretroviral therapy
- **Identify** advantages and disadvantages of long-acting injectable antiretroviral therapy
- **Outline** evidence regarding safety and efficacy of long-acting cabotegravir
- **Summarize** important characteristics of ibalizumab
- **Explain** practical considerations for long-acting injectable antiretroviral therapy

Faculty

Sabeen Ali, PharmD, RPh
PGY1 Pharmacy Practice Resident
Sibley Memorial Hospital

Christopher A. Keeys, PharmD, BCPS, RPh
President, Clinical Pharmacy Associates, Inc.

Fee: N/A



® Howard University College of Pharmacy, (COP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of Continuing Professional Education. **This program meets ACPE criteria for one hour (0.10 CEU).** Credit will be awarded through the CPE Monitor, within 3–4 weeks of the seminar to those who successfully complete the program. Using the following URL: <https://hurxce.learningexpressce.com/index.cfm>, the evaluation form and a score $\geq 70\%$ correct on post-test questions will be required for successful completion. The ACPE Universal Program number assigned to this program is: **0010-0000-20-021-L02-P**. Deadline to claim CE. **08/18/2020**